Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Payables (2023 - 2025)

Compass Therapeutics' Payables history spans 3 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Payables fell 29.52% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, down 29.52%, while the annual FY2025 figure was $1.6 million, 29.52% down from the prior year.
  • Payables for Q4 2025 was $1.6 million at Compass Therapeutics, down from $3.1 million in the prior quarter.
  • Across five years, Payables topped out at $4.1 million in Q4 2023 and bottomed at $724000.0 in Q2 2023.
  • The 3-year median for Payables is $1.6 million (2025), against an average of $1.9 million.
  • The largest annual shift saw Payables plummeted 58.37% in 2024 before it skyrocketed 222.4% in 2025.
  • A 3-year view of Payables shows it stood at $4.1 million in 2023, then crashed by 45.01% to $2.2 million in 2024, then dropped by 29.52% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Payables are $1.6 million (Q4 2025), $3.1 million (Q3 2025), and $2.6 million (Q2 2025).